No abstract

No abstract

A novel process comprising treatment of Taro (Colocasia esculenta (L.) Schott) tuber flour with oxalate oxidase enzyme is developed to deplete the oxalate content. Oxalate oxidase enzyme produced by an endophyte, Ochrobactrum intermedium CL6 is employed to treat taro tuber flour. The treatment followed by extraction of starch results in a 97% reduction in total oxalate content. Further, several physicochemical properties such as paste clarity, swelling power, solubility, amylose content, granule size of starch produced out of enzyme treatment are studied and compared with properties of taro starch produced without enzyme treatment. The study reveals that enzyme treatment does not bring appreciable changes in the studied parameters. The taro starch produced by enzyme treatment shows very low paste clarity (9.38%), high swelling power (15.32 g/g), very low solubility (21.66%), and low amylose content (7.52%) at 100 C compared to potato and sweet-potato starches. X-ray diffraction data reveal that taro starch possesses an A-crystalline form, unlike the B-crystalline form found in potato and sweet potato starch. To the best of the authors knowledge, for the first time, the use of oxalate oxidase to produce oxalate depleted taro starch is reported. One of the interesting food industry applications of oxalate-depleted taro starch, among many other uses could be for baby food formulation because of its small granule size.

No abstract

The aim of the this study is to develop colon targeted drug delivery systems for Ibuprofen using grafted katira gum as a carrier. Polyacrylamide-grafted katira gum was synthesized by grafting acrylamide onto katira gum in presence of varying concentration of ceric ammonium nitrate (CAN) as initiator. Elemental analysis, FTIR, TGA, DTA, DSC, and SEM were used to characterize the grafting of acrylamide onto katira gum. Matrix tablets containing various proportions of grafted katira gum were prepared by wet granulation method. All the formulations were evaluated for hardness, drug content, swelling index, and in vitro release studies in simulated gastric fluid, small intestinal fluid, and simulated colonic fluid with and without enzymes. Ibuprofen was used for controlled release study. The drug release mechanism was studied by fitting into Peppas model and was found to be supercase-II transport. Matrix tablets containing 0.3 g of CAN/gm of acrylamide showed optimum value and retained its physical integrity in simulated gastric, small intestinal and colonic fluid, where as other composition disintegrated within 2 h of dissolution testing in pH 1.2 buffer, simulated gastric fluid. The results of this study indicates that Ibuprofen matrix tablet containing 60 wt % composition of the above grafted katira gum would be potential formulations in delivering the drug to the colon and the more susceptible for enzymatic degradation.